{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,14]],"date-time":"2026-02-14T00:53:57Z","timestamp":1771030437683,"version":"3.50.1"},"reference-count":39,"publisher":"Wiley","issue":"13","license":[{"start":{"date-parts":[[2013,4,10]],"date-time":"2013-04-10T00:00:00Z","timestamp":1365552000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer"],"published-print":{"date-parts":[[2013,7]]},"abstract":"<jats:sec><jats:title>BACKGROUND<\/jats:title><jats:p>The objective of this retrospective study was to investigate the predictive value of pretreatment serum squamous cell carcinoma antigen (SCCAg) levels in 174 patients with squamous cell carcinoma of the anus who received concurrent chemoradiation between 1997 and 2010.<\/jats:p><\/jats:sec><jats:sec><jats:title>METHODS<\/jats:title><jats:p>Pretreatment serum SCCAg measurements in patients with histologically diagnosed squamous cell carcinoma of the anal canal and margin who received chemoradiation were compared with clinical tumor classification and lymph node status for prognostic\/predictive ability, including 1) tumor response after the completion of chemoradiation treatment, 2) disease recurrence, and 3) overall survival. Clinical measurements and scores were compared using Spearman rank tests, and survival was assessed in both univariate and multivariate survival analyses.<\/jats:p><\/jats:sec><jats:sec><jats:title>RESULTS<\/jats:title><jats:p>The median pretreatment levels of SCCAg according to clinical tumor classification and clinical lymph node status were 0.8 \u03bcg\/L in T1 tumors, 1.90 \u03bcg\/L in T2 tumors, 2.5 \u03bcg\/L in T3 tumors, 3.8 \u03bcg\/L in T4 tumors, 1.35 \u03bcg\/L in patients with N0 status, and 3.05 \u03bcg\/L in patients with N0+ status (correlation coefficient: T\u2010classification, 0.43; lymph node status, 0.38; both <jats:italic>P<\/jats:italic>\u2009&lt;\u2009.00001). Of the patients who had normal SCCAg levels, 95% achieved a complete response after initial treatment; and, of those who had elevated SCCAg levels, 86% achieved a complete response (<jats:italic>P<\/jats:italic>\u2009=\u2009.05). Overall survival (hazard ratio, 2.5; <jats:italic>P<\/jats:italic>\u2009=\u2009.007) and disease\u2010free survival (hazard ratio, 2.2; <jats:italic>P<\/jats:italic>\u2009=\u2009.058) were worse for those who had elevated pretreatment serum SCCAg concentrations.<\/jats:p><\/jats:sec><jats:sec><jats:title>CONCLUSIONS<\/jats:title><jats:p>Pretreatment SCCAg levels in patients with squamous cell carcinoma of the anal canal and margin were correlated with clinical tumor classification and clinical lymph node status. Elevated levels of SCCAg were associated with a reduced chance of achieving a complete response and an increased chance of recurrence and death. The authors recommend further studies to determine the prognostic value of SCCAg in anal squamous cell carcinoma and suggest the potential use of SCCAg as a stratification factor in future trials. <jats:bold><jats:italic>Cancer<\/jats:italic> 2013;119:2391\u20102398<\/jats:bold>. \u00a9 <jats:italic>2013 American Cancer Society<\/jats:italic>.<\/jats:p><\/jats:sec>","DOI":"10.1002\/cncr.28055","type":"journal-article","created":{"date-parts":[[2013,4,10]],"date-time":"2013-04-10T11:54:13Z","timestamp":1365594853000},"page":"2391-2398","source":"Crossref","is-referenced-by-count":27,"title":["Squamous cell carcinoma antigen"],"prefix":"10.1002","volume":"119","author":[{"given":"Matt","family":"Williams","sequence":"first","affiliation":[{"name":"Department of Clinical Oncology University College Hospital London United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angela","family":"Swampillai","sequence":"additional","affiliation":[{"name":"Center for Cancer Treatment Mount Vernon Hospital Northwood Middlesex United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Melanie","family":"Osborne","sequence":"additional","affiliation":[{"name":"Department of Oncology Royal Devon and Exeter Hospital Exeter United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suzannah","family":"Mawdsley","sequence":"additional","affiliation":[{"name":"Center for Cancer Treatment Mount Vernon Hospital Northwood Middlesex United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rob","family":"Hughes","sequence":"additional","affiliation":[{"name":"Center for Cancer Treatment Mount Vernon Hospital Northwood Middlesex United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark","family":"Harrison","sequence":"additional","affiliation":[{"name":"Center for Cancer Treatment Mount Vernon Hospital Northwood Middlesex United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard","family":"Harvey","sequence":"additional","affiliation":[{"name":"Medical Oncology Laboratory Department of Clinical Biochemistry Charing Cross Hospital, Imperial College Healthcare National Health Service Trust London United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rob","family":"Glynne\u2010Jones","sequence":"additional","affiliation":[{"name":"Center for Cancer Treatment Mount Vernon Hospital Northwood Middlesex United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"Mount Vernon Colorectal Cancer Network","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2013,4,10]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.20006"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1007\/DCR.0b013e31819eb7f0"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19840701)54:1<114::AID-CNCR2820540124>3.0.CO;2-P"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1997.15.5.2040"},{"key":"e_1_2_7_6_1","first-page":"1049","article-title":"UKCCCR Anal Cancer Trial Working Party. UK Co\u2010ordinating Committee on Cancer Research","volume":"348","author":"Epidermoid anal cancer: results from the UKCCCR randomised trial of radiotherapy alone versus radiotherapy, 5\u2010fluorouracil, and mitomycin","year":"1996","journal-title":"Lancet."},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1996.14.9.2527"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.299.16.1914"},{"key":"e_1_2_7_9_1","doi-asserted-by":"crossref","first-page":"18s","DOI":"10.1200\/jco.2009.27.18_suppl.lba4009","article-title":"A randomized trial of chemoradiation using mitomycin or cisplatin, with or without maintenance cisplatin\/5FU in squamous cell carcinoma of the anus (ACT II) [abstract]","volume":"27","author":"James R","year":"2009","journal-title":"J Clin Oncol."},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.27825"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(197710)40:4<1621::AID-CNCR2820400435>3.0.CO;2-I"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19841015)54:8<1544::AID-CNCR2820540813>3.0.CO;2-B"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1159\/000138979"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0360-3016(98)00147-3"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1525-1438.2006.00449.x"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1159\/000152943"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2010.09.043"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF02049985"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19920701)70:1<35::AID-CNCR2820700106>3.0.CO;2-E"},{"key":"e_1_2_7_20_1","first-page":"275","article-title":"CEA, TPA, CA 19\u20109, SCC and CYFRA at diagnosis and in the follow\u2010up of anal canal tumors","volume":"82","author":"Indinnimeo M","year":"1997","journal-title":"Int Surg."},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF00299336"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2004.01.0454"},{"key":"e_1_2_7_23_1","volume-title":"TNM Classification of Malignant Tumors","author":"Sobin LH","year":"1997"},{"key":"e_1_2_7_24_1","unstructured":"KobayashiE.A Chemiluminescent microparticle squamous cell carcinoma associated antigen assay for the ARCHITECT Instrument System. Paper presented at: 32nd Meeting of the International Society of Oncology and Biomarkers; June 19\u201023 2004; Helsinki Finland."},{"key":"e_1_2_7_25_1","volume-title":"The ARCHITECT Instrument System [product insert]","year":"2004"},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clon.2005.03.008"},{"key":"e_1_2_7_27_1","volume-title":"R Development Core Team. R: A Language and Environment for Statistical Computing","year":"2008"},{"key":"e_1_2_7_28_1","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19890401)63:7<1337::AID-CNCR2820630719>3.0.CO;2-J"},{"key":"e_1_2_7_29_1","doi-asserted-by":"publisher","DOI":"10.3802\/jgo.2010.21.1.18"},{"key":"e_1_2_7_30_1","first-page":"59","article-title":"Evaluation of SCC antigen as a tumour marker for cervical cancer: a co\u2010operative study of GTMG","volume":"3","author":"Crombach G","year":"1988","journal-title":"Tumour Marker Oncol."},{"key":"e_1_2_7_31_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.02.123"},{"key":"e_1_2_7_32_1","doi-asserted-by":"publisher","DOI":"10.1159\/000073846"},{"key":"e_1_2_7_33_1","first-page":"5113","article-title":"The impact of squamous cell carcinoma (SCC) antigen in the follow\u2010up after radiotherapy in patients with cervical cancer","volume":"20","author":"Micke O","year":"2000","journal-title":"Anticancer Res."},{"key":"e_1_2_7_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0360-3016(01)01805-3"},{"key":"e_1_2_7_35_1","doi-asserted-by":"publisher","DOI":"10.1006\/gyno.2001.6497"},{"key":"e_1_2_7_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2007.04.055"},{"key":"e_1_2_7_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1010-5182(98)80020-6"},{"key":"e_1_2_7_38_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2273.1999.00239.x"},{"key":"e_1_2_7_39_1","doi-asserted-by":"publisher","DOI":"10.1002\/bjs.1800760814"},{"key":"e_1_2_7_40_1","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-010-1275-x"}],"container-title":["Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fcncr.28055","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cncr.28055","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T15:13:53Z","timestamp":1760282033000},"score":1,"resource":{"primary":{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/10.1002\/cncr.28055"}},"subtitle":["A potentially useful prognostic marker in squamous cell carcinoma of the anal canal and margin"],"short-title":[],"issued":{"date-parts":[[2013,4,10]]},"references-count":39,"journal-issue":{"issue":"13","published-print":{"date-parts":[[2013,7]]}},"alternative-id":["10.1002\/cncr.28055"],"URL":"https:\/\/doi.org\/10.1002\/cncr.28055","archive":["Portico"],"relation":{},"ISSN":["0008-543X","1097-0142"],"issn-type":[{"value":"0008-543X","type":"print"},{"value":"1097-0142","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,4,10]]}}}